Pharmafile Logo
Pharmafocus logo
Advanced Search

lymphoma

Showing 15 posts of 24 posts found.

Allogene Therapeutics shares updated ALLO-501/501A phase 1 data in large B-cell lymphoma at ASCO annual meeting

June 5, 2023
Research and Development Allogene, LBCL, Oncology, lymphoma, oncology

Allogene Therapeutics has shared updated data from the phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in patients with relapsed/refractory (r/r) large …

News
shutterstock_3

EMA’s CHMP recommends conditional approval for Kite Pharma’s CAR T therapy for mantle cell lymphoma

October 20, 2020
Manufacturing and Production, Sales and Marketing CAR T, CAR-T, CHMP, EMA, kite pharma, lymphoma

Kite Pharma’s anti-CD19 chimeric antigen receptor (CAR) T cell therapy known as KTE-X19 has received positive recommendation from the EMA’s …

News
nice_new_london_office_internal_3_web

NICE rejects mycosis fungoides-type cutaneous T-cell lymphoma therapy over data concerns

August 5, 2020
Research and Development, Sales and Marketing Ledaga, NICE, lymphoma

NICE has announced its rejection of Ledaga (chlormethine gel), a topical therapy for the treatment of mycosis fungoides-type cutaneous T-cell …

News
pd36-1-ksc-20170808-ph_csh01_0023

MSD’s Phase 3 study of lymphoma treatment meets primary endpoints

March 3, 2020
Manufacturing and Production B-cell lymphoma, classical Hodgkin Lymphoma, lymphoma

MSD announced that its Phase 3 study of Keytruda (pembrolizumab) for the treatment of adults with relapsed or refractory classical …

News
roche__tree

EU approval for Roche’s Polivy combo in relapsed/refractory B-cell lymphoma

January 21, 2020
Manufacturing and Production, Sales and Marketing Cancer, Polivy, Roche, lymphoma, pharma

The European Commission has awarded conditional marketing approval to Roche’s Polivy (polatuzumab vedotin), it has been revealed.

News
china_block_001_takeda_0

Takeda commits to advancing treatments for rare bleeding disorders and cancer

December 10, 2019
Manufacturing and Production, Research and Development ASH 19, Cancer, Takeda, lymphoma, oncology

Takeda presented at the 61st American Society of Hematology (ASH) Annual Meeting, 29 company-sponsored abstracts to highlight its commitment to …

News

Roche scores FDA approval for Polivy combo in diffuse large B-cell lymphoma

June 11, 2019
Manufacturing and Production, Sales and Marketing Polivy, Roche, lymphoma, pharma

Roche is celebrating the decision taken by the FDA to approve its anti-CD79b antibody-drug conjugate Polivy (polatuzumab vedotin-piiq) in combination …

News
celgene_building

FDA first as agency expands label on Celgene’s Revlimid in previously treated follicular or marginal zone lymphoma

May 29, 2019
Research and Development, Sales and Marketing Cancer, Celgene, FDA, Revlimid, lymphoma, pharma

Celgene has revealed that the FDA has expanded its authorised indications of Revlimid (lenalidomide) to include combination with a rituximab …

News
takeda_usa_pharmaceuticals_u

NICE recommend Takeda’s lymphoma treatment Adcetris

March 25, 2019
Sales and Marketing Cancer, NICE, Takeda, UK, lymphoma, oncology, recommendation

Britain’s cost effectiveness body has recommended Takeda’s Adcetris (brentuximab vedotin) for adult patients with CD-30 positive advanced cutaneous T-cell lymphoma …

News
kymriah

Novartis’ CAR-T therapy Kymriah gets NICE green light in diffuse large B-cell lymphoma

February 1, 2019
Medical Communications, Sales and Marketing CAR-T, Cancer, Kymriah, NICE, Novartis, lymphoma, pharma

NICE has announced another momentous decision for lymphoma patients in England and Wales:, recommending Novartis’ chimeric antigen receptor T cell …

News
shutterstock_212035546

Epizyme shuts down failing lymphoma trial as FDA imposes clinical hold

August 3, 2018
Medical Communications, Research and Development Epizyme, FDA, lymphoma, pharma, tazemetostat

Epizyme’s Q2 financial results have been derailed by the company’s decision to terminate further Phase 2 development of its lead …

News
celgene_building

Celgene’s Revlimid combo meets Phase 3 goal in relapsed/refractory indolent lymphoma

July 24, 2018
Manufacturing and Production, Research and Development Celgene, Revlimid, lymphoma, pharma

Celgene has lifted the curtain on new Phase 3 data for its combo of Revlimid (lenalidomide) plus rituximab (R2) in …

News
shutterstock_159488225

Blood cancer patients over 75 are significantly underrepresented in clinical trials, study finds

December 13, 2017
Research and Development FDA, blood cancer, leukaemia, lymphoma, myeloid leukaemia, pharma

The FDA’s first comprehensive analysis of clinical trial enrolment in older patients with blood cancers has revealed that the population …

News
800px-cancer_cells_1

New research reports first-ever response of central nervous tumour to CAR T therapy

August 29, 2017
Manufacturing and Production, Research and Development CAR T, CAR-T, Cancer, life sciences, lymphoma, medicine, pharma, pharmaceuticals

Researchers at a General Hospital in Massachusetts has reported what they claim is the first response of a nervous system …

News

Roche antibody becomes first of its kind authorised for blood cancer

July 26, 2017
Research and Development, Sales and Marketing CDF, Cancer, NICE, drugs, lymphoma, pharma, pharmaceutical Roche

NICE has announced its decision to make Roche’s Gazyvaro available via the Cancer Drugs Fund (CDF) in combination with chemotherapy …

News

Latest content

Sanofi and Teva partner for development of inflammatory bowel disease treatment

October 4, 2023

Eli Lilly to acquire POINT Biopharma

October 4, 2023

Acurx Pharmaceuticals announces positive data from phase 2b trial for C. difficile infection treatment

October 3, 2023

WHO recommends new vaccine for prevention of malaria in children

October 3, 2023

FDA grants marketing authorisation to DNA test for predisposition to certain cancers

October 2, 2023